3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial

Journal:
The Lancet Diabetes & Endocrinology
Published:
DOI:
10.1016/s2213-8587(25)00319-5
Affiliations:
4
Authors:
7
Go to article
Institutions Authors Share
Massachusetts General Hospital (MGH), United States of America (USA)
6.000000
 0.86
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM), United States of America (USA)
1.000000
 0.14
Interested in Clinical Sciences?